Alcon acquires majority stake in Aurion Biotech
Alcon (SIX/NYSE: ALC), the global leader in eye care, announced today its acquisition of a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies for treating eye diseases. The move aims to advance Aurion’s promising allogeneic cell therapy…